Deals
Actelion, J&J Are Back in Exclusive Talks a Week After Breakup
- Drugmakers entered exclusive talks about a potential deal
- Actelion calls possible transaction ‘strategic;’ shares up
Actelion, J&J Enter in Surprise Exclusive Talks
This article is for subscribers only.
In a surprise twist to one of 2016’s biggest potential health deals, Actelion Ltd. and U.S. drug giant Johnson & Johnson are back at the negotiating table just a week after ending earlier talks.
This time, the companies entered into exclusive discussions about a possible transaction that Switzerland-based Actelion, in a statement Wednesday, called “strategic.” There can be no assurance any transaction will result from these talks, both companies said, without providing further details.